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The efficacy of sodium stibogluconate against Leishmuniu donovani infections was markedly enhanced by encapsulating 
this drug in tuftsin-bearing liposomes. Also, pretreatment of the animals with these liposomes (free of drug) rendered 
them resistant o this infection, possibly by activating the host’s macrophages. These results demonstrate that tuftsin- 
bearing liposomes besides delivering the drug to the target cells could also enhance the nonspecific resistance against 
infections, thus offering an additional advantage over the use of tuftsin-free liposomes as drug carriers in leishmania 
therapy. 
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1. INTRODUCTION 
Liposomes bearing cell-specific ligands on their 
surface may prove useful as vehicles for site- 
specific delivery of drugs in biophase [1,2], but 
their successful application in therapy is limited by 
their inherent tendency to concentrate in 
reticuloendothelial cells [3]. Since in the case of 
leishmaniasis, the causative organism is located 
within these very cells, the liposome-mediated 
delivery of drugs in treatment of this infection 
seems to be highly promising [4]. 
We have developed liposomes which specifically 
recognize the phagocytic cells, including 
macrophages [5]. These liposomes besides deliver- 
ing their contents to the target cells [5] have also 
been shown to enhance the host’s resistance 
against parasitic infections [6]. This property has 
been conferred to these liposomes by tuftsin, 
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which is known to specifically bind macro- 
phages/monocytes [7], and also potentiates the 
natural killer activity of these cells [7]. 
To evaluate further the usefulness of tuftsin- 
bearing liposomes in parasitic diseases, we have 
now examined the effect of these liposomes on 
Leishmania donovani infections in hamsters. Also, 
we have attempted to use these liposomes as 
vehicles for delivering the antileishmanial drug, 
sodium stibogluconate, to the infected animals. 
The data shown here clearly indicate that these 
liposomes not only enhance the resistance of 
hamsters to L. donovani infection, but are also 
very effective in increasing the efficacy of sodium 
stibogluconate in leishmaniasis treatment. 
2. MATERIALS AND METHODS 
2.1. Tuftsin 
Tuftsin was modified at the C-terminus (Thr-Lys-Pro-Arg- 
NH-(CH&-NH-COC15H31) to facilitate its incorporation in the 
liposome bilayer. Both tuftsin and modified tuftsin were 
prepared as in [5]. 
2.2. Liposomes 
Liposomes were prepared from egg phosphatidylcholine 
(20 pmol) and cholesterol (10 rmol) with or without modified 
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tuftsin (7-W% by phospholipid weight) in 1 ml T&buffered 
saline (10 mM Tris containing 150 mM NaCl, pH 7.4) by 
probe-type sonication, and fractionated by centrifugation [8]. 
For loading the liposomes with drug, sodium stibogluconate 
(about 410 rmol based on pentavalent antimony) was included 
in the above buffer, prior to sonication. Free and liposomised 
drugs were separated by gel filtration over Sephadex G-50. The 
amount of the liposome-encapsulated drug was determined by 
estimating pentavalent antimony [9]. The extent of incorpora- 
tion of modified tuftsin in the liposome bilayer was measured 
following the published procedure [5]. Lower doses of drug en- 
capsulated in liposomes were prepared by appropriate dilution 
of the preformed drug-loaded liposomes with suitable buffer. 
2.3. Animals 
Male golden hamsters (Mesocricetus auratus) and Balb/C 
mice (weight 18-22 g) were used in all the experiments. 
2.4. Parasites 
The Leishmania donovani strain (HOM/IN/80/Dd 8), 
originally isolated from a Kala-azar patient from Bihar (India), 
was a kind gift from Professor P.C.C. Garnham. The strain is 
being regularly maintained in vitro as promastigotes in NNN 
medium, and as amastigotes in golden hamsters. 
2.5. Infection 
2.5.1. For chemotherapeutic studies 
Amastigotes were isolated from the spleen of infected 
hamsters (with more than 2 months of infection). These were 
suspended in Locke’s solution (8 g NaCl, 0.2 g KCl, 0.2 g 
CaClz, 0.3 g KH2P04 and 2.5 g glucose in 1 1, pH 7.2) to about 
10s amastigotes/ml. A measured portion (0.1 ml) of this 
suspension was administered intracardiacly (i.c.) to each 
hamster (weight 40-45 g). The animals developed 2 + infection 
(5-20 amastigotes/lOO spleen cell nuclei) after 25-30 days, 
which was assessed by spleen biopsies. There was no effect of 
the operative trauma on the course of L. donovani infection, 
since we observed no difference in the intensity of infection 
determined by two independent methods, namely autopsy and 
spleen biopsy. 
2.5.2. For prophylactic studies 
Golden hamsters were challenged with 10’ promastigotes 
(i.c.) in 0.1 ml Locke’s solution. These promastigotes were 
derived from the in vitro cultures and washed with Locke’s 
solution prior to use. In all the experiments, promastigotes were 
isolated from the infected spleen of hamsters in primary 
cultures, and used after 5-8 subcultures in vitro. 
2.5.2. In in vitro macrophage cultures 
Peritoneal macrophages of Balb/C mice were harvested in 
RPMI-1640 medium containing heparin, using standard pro- 
cedures. These were washed twice and resuspended in complete 
RPMI-1640 medium supplemented with 10% fetal calf serum, 
gentamycin (40 pg/ml medium) and 40 mM 2-[tris(hydrox- 
ymethyl)methyl amino]-1-ethane sulfonic acid (Tes). The final 
suspension was made to about lo6 macrophages/ml, and seeded 
into Leighton tubes with cover slips. On the following day, 
medium from each tube was removed and replaced with com- 
plete medium containing 2 x lo6 promastigotes/ml. These pro- 
mastigotes could infect the macrophages, and developed into 
amastigotes inside these cells. Cultures were incubated in special 
gas chambers with a gas mixture of 5% 02, 5% CO2 and 90% 
N2. 
2.6. Treatment 
2.6.1. Chemotherapeutic treatment 
Hamsters (weight 80-85 g) with 4-28 amastigotes/lOO spleen 
cell nuclei, as assessed between day 25 and day 30 post-infection 
by spleen biopsy, were divided into four groups. Each group 
consisted of a large number of animals with 4-5 animals for 
each test dose. Animals in group I were given free sodium 
stibogluconate; group II, drug entrapped in tuftsin-free 
liposomes; and group III, drug entrapped in tuftsin-bearing 
liposomes. These preparations were administered i.c. only once, 
3-4 days after the spleen biopsy. The fourth group was the con- 
trol group, which was administered buffer only. On day 7 and 
day 28 post-infection, spleen biopsies were carried out again, 
and spleen smears after Giemsa staining were assessed for 
amastigote counts. Inhibition of amastigote multiplication was 
calculated using the following equation: PI = 
100 - (AN x lOO)/(INA x TI) where AN, actual number of 
amastigotes/lOO spleen cell nuclei after treatment; INA, initial 
number of amastigotes/lOO spleen cell nuclei; TI, fold increase 
in the number of amastigotes in control animals on the cor- 
responding day of the biopsy in treated animals; and PI, 
percentage inhibition. 
2.6.2. Prophylactic treatment 
Hamsters (weight 40-45 g) were divided into five groups, 
each having 3-7 animals. Group I was administered with a 
single dose (60/1g/animal, i.c.) of free tuftsin, group II with 
free tuftsin for 3 consecutive days (60 &animal per day, i.c.), 
group III with a single dose of liposomal tuftsin (60 ,ug/animal, 
i.c.), group IV with liposomal tuftsin for 3 consecutive days 
(6O/cg/animal per day, i.c.), and group V, the control group, 
was injected (i.c.) with saline only. Seven days after the first in- 
jection all the animals were challenged with 10’ promastigotes. 
Spleen biopsies were performed on day 30, day 45 and day 60 
post-infection, and the percentage inhibition (PI) was 
calculated using the following equation: PI = 
100 - (NAE x lOO)/(MNAC) where NAE, number of 
amastigotes/lOO spleen cell nuclei in experimental nimals; and 
MNAC, mean number of amastigotes/lOO spleen cell nuclei in 
control animals. 
2.7. Susceptibility of peritoneal macrophages of free and 
liposomised tuftsin-treated Balb/C mice to L. donovani 
infection 
Male Balb/C mice were used in 3 groups, each consisting of 
4-5 animals. These were separately given saline, free tuftsin 
(75 fig/animal per day) and liposomised tuftsin (75 pg/animal 
per day) intravenously on 3 consecutive days. Seven days after 
the first injection, these animals were killed, and peritoneal 
macrophages were isolated, washed and seeded in Leighton 
tubes with cover slips, after suspending them in RPMI-1640 
medium containing 10% fetal calf serum. Each tube contained 
about lo6 macrophages/ml. On the following day, about 2 x 
lo6 promastigotes were added to each tube. Cover glasses with 
attached macrophages were removed from the culture tubes on 
day 2 and day 5 post-infection, fixed with absolute methanol, 
stained with Giemsa and percentage of macrophages infected as 
well as average number of amastigotes/cell were determined. 
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3. RESULTS AND DISCUSSION 
Maximum effect of sodium stibogluconate on L. 
donovani infection in hamsters was observed when 
this drug was given at 10 mg/kg per day for five 
consecutive days. This treatment produced over 
90% inhibition of the infection on day 28 post- 
treatment. The extent of this inhibition was con- 
siderably reduced when the infected hamsters were 
treated with this drug at 250/g or 5OOrg/kg for 
one day only (table 1). However, single treatment 
by these reduced drug doses was very effective 0, < 
0.01) after encapsulating the drug in liposomes 
(table 1). At a 500/1g/kg dose, the drug encap- 
sulated in tuftsin-bearing liposomes showed much 
better (p < 0.01) effects than that delivered in the 
tuftsin-free liposomes on day 28 post-treatment. 
But this difference was reduced (p c 0.01 on day 
7 but > 0.05 on day 28 post-treatment) by reducing 
the drug dose to 250yg/kg, although at this dose 
the liposomised drug exhibited the maximum an- 
tileishmanial activity. Further decrease in the 
liposomised drug dose resulted in decreased 
biological activity and no differences were ob- 
served between the effects of drug encapsulated in 
tuftsin-free and tuftsin-bearing liposomes (data 
not shown). 
These findings indicate that encapsulation of 
sodium stibogluconate in tuftsin-bearing lipo- 
somes significantly @ < 0.01) enhances the drug 
efficacy against L. donovani infection. Since the 
causative organism of this disease primarily resides 
within the macrophages which have been shown to 
possess on their surface the specific binding sites 
for tuftsin [7], it may be inferred that the observed 
enhanced efficacy of the drug encapsulated in 
tuftsin-bearing liposomes against L. donovani in- 
fection could be due to the enhanced uptake of 
these drug-loaded liposomes by the macrophages 
of infected hamsters. Here, it may be mentioned 
that our failure to observe the enhanced an- 
tileishmanial effect of the drug loaded in tuftsin- 
bearing liposomes, as compared to that in the 
tuftsin-free liposomes, at low drug doses 
(<250 pg/kg) is possibly due to dilution of the 
tuftsin-bearing liposomes below their optimal con- 
centration required to observe their enhanced up- 
take by the host’s macrophages [5]. 
Our previous studies [6] have shown that mice 
pretreated with the tuftsin-bearing liposomes 
strongly resist Plasmodium berghei infection. To 
ascertain whether similar treatment of hamsters 
would render them resistant o L. donovani infec- 
tion, we studied the course of this infection in the 
animals pretreated with free and liposomal tuftsin. 
Fig. 1 shows that pretreatments with both free and 
liposomal tuftsin provided protection against L. 
donovani. However, the inhibitory effect on this 
infection was greater 01 < 0.01 on day 30 post- 
infection for single treatment) when tuftsin was in- 
corporated in the liposome bilayer. Moreover, a 
single treatment with tuftsin or liposomal tuftsin 
was more effective than ‘the multiple treatment. 
These results clearly show that the pretreatment of 
Table 1 
Effect of liposomised sodium stibogluconate on L. donovani infection in hamsters 
Preparationa Drug dose % inhibition of infectionb 
kg/kg) (on day post-treatment) 
7th 28th 
Survival of animals 
(on day post- 
treatment) 
7th 28th 
F 500 35.8 + 6.6 Dead 4/4 o/4 
L 500 65.0 f 6.1 61.5 f 1.3 4/4 2/4 
L-T 500 77.6 + 1.8 85.0 + 3.1 4/4 414 
F 250 51.9 f 4.7 Dead 4/4 o/4 
L 250 74.8 + 5.1 80.5 f 11.6 515 415 
L-T 250 86.5 f 4.5 92.1 + 2.7 4/4 4/4 
a F, free drug; L, drug entrapped in tuftsin-free liposomes; L-T, drug entrapped 
in tuftsin-bearing liposomes 
b Values shown are mean of 4-5 animals + SD 
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Fig. 1. Prophylactic effect of tuftsin on L. donovoni infection in 
hamsters. (A) Free tuftsin; (B) liposomal tuftsin. Solid and 
broken lines represent reatments with single and triple doses, 
respectively. Values are shown as both mean and range. For 
details, see section 2. All the animals survived up to day 45 in 
the treated groups, but on day 60 the survival in these groups 
was as follows: animals treated with single and triple doses of 
free tuftsin, 30% and 0% survival, respectively; animals treated 
with single and triple doses of liposomal tuftsin, over 60% 
survival. In the control group, only 50% and 30% of the 
animals survived on day 45 and day 60, respectively. 
animals with liposomal tuftsin considerably 
enhances their resistance to leishmania infection. 
To analyse whether the increased resistance of 
the tuftsin-pretreated animals to the infection is 
due to the tuftsin-mediated activation of the host’s 
macrophages [7], we examined the susceptibility of 
the peritoneal macrophages, derived from the 
pretreated animals, to L. donovani infection in 
vitro. Fig.2 shows that the infection of 
macrophages was markedly reduced when these 
cells were derived from the liposomal tuftsin- 
pretreated animals. Also, the parasite multiplica- 
tion inside such macrophages was considerably 
decreased, as compared to the macrophages of un- 
treated animals. These findings demonstrate that 
pretreatment of animals with tuftsin-bearing 
liposomes renders their macrophages refractory to 
L. donovani infections. 
This study clearly shows that the efficacy of 
sodium stibogluconate against leishmania infec- 
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Fig.2. Susceptibility to L. donovani infection in vitro of 
macrophages derived from tuftsin-treated Balb/C mice. Values 
shown are mean of several determinations f SD. (Solid bars) 
Macrophages derived from untreated animals; (open bars) 
macrophages derived from tuftsin-treated animals; (shaded 
bars) macrophages derived from liposomal tuftsin-treated 
animals. 
tion is greatly increased by encapsulating this drug 
in tuftsin-bearing liposomes. Also, it demonstrates 
that pretreatment of animals with tuftsin-bearing 
liposomes (free of drug) considerably enhances 
their resistance to this infection, possibly by ac- 
tivating the host’s macrophages. It would 
therefore seem that these liposomes besides 
delivering the drug to the macrophages could also 
activate these cells for nonspecific killing of the 
pathogen, thus offering an additional advantage 
over the use of tuftsin-free liposomes as drug car- 
riers in leishmania therapy [4]. 
Apart from L. donovani, several other 
pathogens, such as Mycobacterium leprae, 
Mycobacterium tuberculosis, human immunodefi- 
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ciency virus, etc., thrive inside the macronhaaes, REFERENCES 
which essentially results in an impairment of-the 
host’s nonspecific immune defence mechanisms 
against infections. In such situations, use of 
tuftsin-bearing liposomes as drug vehicles may 
prove highly advantageous, since these liposomes 
besides ensuring drug delivery to the target cells 
would also stimulate the killer activity of the 
phagocytic cells. We, therefore, conclude that 
these liposomes could find a useful application in 
macrophage-based infections, in general. 
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